(Q84409904)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21693296%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

title

Long-term maintenance therapy for post-cardiac transplant monoclonal lymphoproliferative disorder: caveat mammalian target of rapamycin (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21693296%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21693296%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

author name string

Z Khalpey

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21693296%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

D V Miller

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21693296%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

S S Kushwaha

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21693296%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

publication date

1 June 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21693296%20AND%20SRC:MED&resulttype=core&format=json

Transplantation Proceedings

5 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21693296%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

volume

43

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21693296%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21693296%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

page(s)

1893-1899

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21693296%20AND%20SRC:MED&resulttype=core&format=json

Norman Edward Shumway - pioneer of cardiac surgery (February 9, 1923 to February 10, 2006)

5 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2011.03.033

Cardiac allograft vasculopathy: pathology, prevention and treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2011.03.033

Pattern of changes over time in myocardial blood flow and microvascular dilator capacity in patients with normally functioning cardiac allografts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2011.03.033

Mechanisms of chronic rejection in cardiothoracic transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2011.03.033

National conference to assess antibody-mediated rejection in solid organ transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2011.03.033

The mechanism of action of cyclosporin A and FK506.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2011.03.033

Increased plasma homocysteine concentrations accelerate cardiac allograft vasculopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2011.03.033

Proliferation signal inhibitors in cardiac transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2011.03.033

Replacement of calcineurin-inhibitors with sirolimus as primary immunosuppression in stable cardiac transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2011.03.033

Conversion to sirolimus as primary immunosuppression attenuates the progression of allograft vasculopathy after cardiac transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2011.03.033

Epstein-Barr virus-negative post-transplant lymphoproliferative disorders: a distinct entity?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2011.03.033

Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2011.03.033

Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2011.03.033

EBV PCR in the diagnosis and monitoring of posttransplant lymphoproliferative disorder: results of a two-arm prospective trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2011.03.033

Constitutive activation of mTOR signaling pathway in post-transplant lymphoproliferative disorders.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2011.03.033

Successful management of recurrent Epstein-Barr virus-associated multilocular leiomyosarcoma after cardiac transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2011.03.033

Sirolimus-induced remission of posttransplantation lymphoproliferative disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2011.03.033

Resolution of renal allograft-associated post-transplant lymphoproliferative disorder with the introduction of sirolimus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2011.03.033

Sirolimus for pediatric liver transplant recipients with post-transplant lymphoproliferative disease and hepatoblastoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2011.03.033

Post-transplant lymphoproliferative disorder--the potential of proliferation signal inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2011.03.033

Prognostic analysis for survival in adult solid organ transplant recipients with post-transplantation lymphoproliferative disorders.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2011.03.033

Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2011.03.033

Lymphoma after solid organ transplantation: risk, response to therapy, and survival at a transplantation center.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2011.03.033

Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2011.03.033

Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2011.03.033

Successful treatment of T-cell post-transplant lymphoproliferative disorder with the retinoid analog bexarotene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2011.03.033

mTOR inhibition and its effect on cancer in transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2011.03.033

Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2011.03.033

The role of mTOR inhibitors in the management of posttransplant malignancy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2011.03.033

Low incidence of malignancy among sirolimus/cyclosporine-treated renal transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2011.03.033

10.1016/J.TRANSPROCEED.2011.03.033

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21693296%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

1 reference